Drug Database · Clinicians

Atropine + Hyoscine + Hyoscyamine

Also known as: scopolamine (US name, for hyoscine)

Brands (1) DonnatabShow all

Antispasmodic PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: ATROPEN is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. US FDA label

  • Hyoscine-n-butylbromide listed as hyoscine

    Use: Gastrointestinal and genitourinary spasm (tablets) renalcarematters.com, reviewed

    Kidney dosing: Hyoscine-n-butylbromide (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    Tablets: 10 to 20 mg per dose, maximum 60 mg/day. Injection: 10 to 20 mg slowly IV, IM or SC, maximum 100 mg/day (PM).
    CrCl 30–59 mL/min
    The prescribing information gives no kidney dosing. Tablets: negligible absorption, kidney accumulation unlikely. Injection: about half of an intravenous dose is excreted unchanged in urine; use the lowest dose and watch for anticholinergic effects.
    CrCl 15–29 mL/min
    The prescribing information gives no kidney dosing. Tablets: negligible absorption, kidney accumulation unlikely. Injection: about half of an intravenous dose is excreted unchanged in urine; use the lowest dose and watch for anticholinergic effects.
    CrCl <15 mL/min (not on dialysis)
    The prescribing information gives no kidney dosing. Tablets: negligible absorption, kidney accumulation unlikely. Injection: about half of an intravenous dose is excreted unchanged in urine; use the lowest dose and watch for anticholinergic effects.
    Hemodialysis (intermittent)
    Not studied in dialysis; no dose given.
    Peritoneal dialysis
    Not studied in dialysis; no dose given.
    CRRT
    Not studied in dialysis; no dose given.
    • Dialyzable? Not stated.
    • Monitoring Anticholinergic effects: urinary retention, tachycardia, hypotension after injection (observe; emergency equipment available), raised intraocular pressure (urgent review for painful red eye). Avoid IM injection in anticoagulated patients (PM).

    From the Hyoscine-n-butylbromide monograph (renalcarematters.com, reviewed).

  • hyoscyamine no separate page

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Tablet: 103.7 mcg/19.4 mcg/6.5 mcg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Atropine + Hyoscine + Hyoscyamine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Atropine + Hyoscine + Hyoscyamine
Package insert
DonnatabHyoscyamine Sulfate + Atropine Sulfate + Hyoscine Hydrobromide
103.7 mcg/19.4 mcg/6.5 mcg TabletBlister Pack x 25's (Box of 25's and 50's)
Rx
Interphil Laboratories, Inc.Philippines
—
DR-XY31283 (FOR EXPORT ONLY)
Nov 24, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .